Skip to content

Study · Non-randomized trial · n = 19 · 2019

3 results

Intranasal glucagon acutely increases energy expenditure without inducing hyperglycaemia in overweight/obese adults.

Stahel P, Lee SJ, Sud SK, Floh A, Dash S

Diabetes, obesity & metabolism4 Mar 2019Cited by 15 (Europe PMC)

PMID30740846 (opens in a new tab)DOI10.1111/dom.13661 (opens in a new tab)PepBankPUB-30740846
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In overweight or obese adults, intranasal glucagon increased total resting energy expenditure to 69.4 ± 1.2 versus 61.5 ± 1.2 kcal with placebo.

    In plain wordsIn overweight or obese adults, intranasal glucagon increased resting energy expenditure compared with placebo.

    Peptide
    Glucagon
    Outcome
    IncreaseResting energy expenditure
    Study

    n = 19

    Comparator
    intranasal placebo
    Outcome group
    Energy expenditure and thermogenesis · Metabolic and weight
    Studied dose
    0.7 mg · intranasalAs given in this study (human).

    Measurements

    Total REE
    69.4 kcal
    intranasal glucagon
    Total REE (± value, type not stated)
    1.2 kcal
    intranasal glucagon
    Total REE
    61.5 kcal
    intranasal placebo
    Total REE (± value, type not stated)
    1.2 kcal
    intranasal placebo
    P value
    0.027
    between treatments

    Source sentences

    Summary
    ING increased total REE (INP 61.5 ± 1.2 kcal vs ING 69.4 ± 1.2 kcal; P = 0.027).
    2 context sentences
    Summary · context
    To assess the acute effects of 0.7 mg intranasal glucagon (ING) vs intranasal placebo (INP) on food intake and resting energy expenditure (REE).
    Summary · context
    A single-blind, crossover study was conducted in 19 overweight/obese adults (15 men, 4 women).
  2. 02HumanNon-randomized trialEfficacy outcome

    In overweight or obese adults, blood glucose, food intake and appetite did not differ between intranasal glucagon and placebo.

    In plain wordsIn overweight or obese adults, blood glucose, food intake and appetite did not differ between intranasal glucagon and placebo.

    Peptide
    Glucagon
    Outcome
    No significant changeBlood glucose, food intake and appetite
    Study

    n = 19

    Comparator
    intranasal placebo
    Outcome group
    Cardiometabolic risk factors · Metabolic and weight
    Studied dose
    0.7 mg · intranasalAs given in this study (human).

    Source sentences

    Summary
    There were no between-treatment differences in blood glucose, food intake and appetite.
    2 context sentences
    Summary · context
    To assess the acute effects of 0.7 mg intranasal glucagon (ING) vs intranasal placebo (INP) on food intake and resting energy expenditure (REE).
    Summary · context
    A single-blind, crossover study was conducted in 19 overweight/obese adults (15 men, 4 women).
  3. 03HumanNon-randomized trialSafety outcome

    In overweight or obese adults, the intranasal glucagon study reported no adverse effects.

    In plain wordsIn overweight or obese adults, the intranasal glucagon study reported no adverse effects.

    Peptide
    Glucagon
    Outcome
    Not applicableAdverse effects
    Study

    n = 19

    Comparator
    intranasal placebo
    Outcome group
    Adverse events · Whole body
    Studied dose
    0.7 mg · intranasalAs given in this study (human).

    Source sentences

    Summary
    There were no adverse effects.
    2 context sentences
    Summary · context
    To assess the acute effects of 0.7 mg intranasal glucagon (ING) vs intranasal placebo (INP) on food intake and resting energy expenditure (REE).
    Summary · context
    A single-blind, crossover study was conducted in 19 overweight/obese adults (15 men, 4 women).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.